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Abstract: Non-small cell lung cancer (NSCLC) is still the leading cause of cancer death worldwide. 
Despite the introduction of tyrosine kinase inhibitors and immunotherapeutic approaches, there is 
still an urgent need for novel strategies to improve patient survival. ROS1, a tyrosine kinase receptor 
endowed with oncoantigen features, is activated by chromosomal rearrangement or overexpression 
in NSCLC and in several tumor histotypes. In this work, we have exploited transgenic mice 
harboring the activated K-Ras oncogene (K-RasG12D) that spontaneously develop metastatic NSCLC 
as a preclinical model to test the efficacy of ROS1 immune targeting. Indeed, qPCR and 
immunohistochemical analyses revealed ROS1 overexpression in the autochthonous primary 
tumors and extrathoracic metastases developed by K-RasG12D mice and in a derived transplantable 
cell line. As proof of concept, we have evaluated the effects of the intramuscular electroporation 
(electrovaccination) of plasmids coding for mouse- and human-ROS1 on the progression of these 
NSCLC models. A significant increase in survival was observed in ROS1-electrovaccinated mice 
challenged with the transplantable cell line. It is worth noting that tumors were completely rejected, 
and immune memory was achieved, albeit only in a few mice. Most importantly, ROS1 
electrovaccination was also found to be effective in slowing the development of autochthonous 
NSCLC in K-RasG12D mice.  
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1. Introduction 
Lung cancer is still one of the major unresolved issues in the oncology panorama [1]. Overall, 
around 80%–85% of lung cancer cases can be classified as non-small cell lung cancer (NSCLC) [2,3]. 
The best option for long-term survival is surgery when NSCLC is diagnosed in its early stages and is 
resectable [4–6]. Unfortunately, the five-year survival is poor even in this case, although there is little 
improvement if patients are treated with neoadjuvant and/or adjuvant chemotherapy [7–10]. Instead, 
when NSCLC is diagnosed in advanced or metastatic stages, which occurs in more than 70% of 
patients, a dramatically worse prognosis is observed, with a 5-year survival of less than 10% when 
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using conventional therapeutic options, including a combination of chemotherapy and radiotherapy 
[5,11]. Significant improvements in overall survival have been observed in advanced NSCLC patients 
treated with checkpoint inhibitors (CIs), such as monoclonal antibodies (mAbs) that target PD-1 
(nivolumab and pembrolizumab) and PD-L1 (atezolizumab), compared to patients treated with 
chemotherapy and radiotherapy alone [12–15]. However, there is great heterogeneity in the patient 
response to therapy, including acquired resistance [16], and complete responses are rare [6,17,18]. 
Moreover, patients often experience significant immune-related adverse effects [19,20]. 
In addition to CIs, molecular-targeted therapies against the most common NSCLC drivers (the 
mutated epidermal growth factor receptor, EGFR, and the translocated anaplastic lymphoma kinase, 
ALK) have been developed and clinically approved [21–24]. Although effective tumor shrinking and 
disease control have been observed, acquired resistance is still an unavoidable problem and new 
approaches that target these molecules are needed. 
Another important issue in the management of advanced NSCLC is to expand the spectrum of 
subtypes that are eligible for targeted therapy by identifying other driver alterations besides the 
already known EGFR and ALK. With this in mind, we have focused on the c-ros oncogene 1 receptor 
tyrosine kinase (ROS1), an orphan tyrosine kinase receptor whose aberrant activation has been 
implicated with enhanced tumor cell growth, proliferation, metastasization, and resistance to 
chemotherapy [25–27]. The most common activating alterations of ROS1 in NSCLC are gene fusion 
with the solute carrier family 34 member 2 (SLC34A2) and CD74, as well as protein overexpression, 
gene amplification and mutations [28–31]. Although the reported frequency of these alterations in an 
unselected NSCLC population is estimated to be <3% [32–34], they rarely overlap with EGFR 
mutations and ALK fusions [35] and are prevalent in young, never-smoker patients [36,37], defining 
ROS1-positive NSCLC as a unique subset of patients with a potentially targetable driver oncogene. 
The proven existence of an evolutionary link between ROS1 and ALK receptors [38,39] has led 
to the Food and Drug Administration (FDA) approval of the ALK inhibitor crizotinib [39,40] for the 
treatment of advanced ROS1-rearranged NSCLC in 2016 [41,42] and finally to its recommendation as 
standard-of-care for advanced NSCLC patients with known ROS1 alterations [43]. Unfortunately, as 
it has already been described for ALK-positive NSCLC patients, resistance to crizotinib occurs as a 
consequence of secondary mutations in the ROS1 tyrosine kinase domain [44].  
The immune targeting of tyrosine kinases is a promising alternative, or complement, to tyrosine 
kinase inhibitor-based targeted therapies [45,46]. When tyrosine kinases, such as ROS1, are expressed 
on the plasma membrane, their immune targeting can either be achieved via the passive 
administration of mAbs or by actively immunizing the patient against the tyrosine kinase. The 
potential of the passive administration of mAbs against different tumor associated antigens [47,48] 
has been demonstrated by several approved clinical protocols. However, mAbs are biologic products, 
with a short-lived therapeutic action, that can elicit a number of adverse events [49]. Among them, 
mAb-related infusion problems, sometimes associated with acute hypersensitivity [50], may arise. 
Other than the well-known dermatologic and cardiac toxicities [51], a number of gastrointestinal, 
endocrine, and other inflammatory reactions have been described, which are related to the unbalance 
between immune recognition and tolerance [49]. Moreover, the development by the patient's immune 
system of neutralizing antibodies directed against the mAbs and the possible tumor antigen mutation 
occurring in the epitope recognized by the mAbs are responsible for the tumor relapse observed in 
most treated patients. In this contest, the concomitant induction of a polyclonal antibody and T-cell 
response induced by active immunization through therapeutic vaccines offers the possibility to 
overcome these issues. Moreover, the specific long-lasting immunological memory elicited by the 
patient’s own immune system could limit the number of treatments needed for each patient and, 
most importantly, the side effects associated with mAb administration. 
The endowed properties of ROS1, i.e. its prevalent expression in cancer cells, in which it plays a 
clear key oncogenic role, and its limited expression on healthy tissues, make it an ideal oncoantigen 
to target with vaccination [52]. Among the vaccination strategies used until now, gene-based vaccines 
have been shown to possess a number of advantages compared to cell- and protein/peptide-based 
vaccines, being a relatively simple and very flexible way of activating the immune response in animal 
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models against a specific antigen [53–55]. However, simple naked plasmid DNA injection is 
accompanied by limited uptake and a consequent inadequate antigen transcription by transfected 
cells [56], and this is particularly evident when naked DNA vaccines are scaled up from smaller 
species such as mice and rats to non-human primates and humans [57,58]. This issue can be overcome 
through the use of the in vivo intramuscular electroporation of DNA plasmids (electrovaccination) 
that has been one of the most effective strategies among the innovative delivery methods exploited 
until now [59–62]. The principle behind electrovaccination efficacy is strikingly simple: the brief 
electrical pulses applied in the site of DNA injection create transient ‘pores’ in the muscle cell 
membranes that allow the DNA to easily enter into the cell cytoplasm [63]. Immediately following 
cessation of the electrical field, the pores seal without causing cell death. The increased DNA vaccine 
cellular uptake leads to an amplified protein expression and to an enhanced immune response against 
the target antigen [64–66]. Moreover, electroporation itself works as an adjuvant, since it induces a 
local inflammation at the injection site and the generation of a pro-immunogenic microenvironment 
[66,67]. Several devices that ensure safe, tolerable, reproducible, and clinically acceptable in vivo DNA 
plasmid electroporation have been introduced [68,69] and, in this regard, the Cliniporator (IGEA Srl, 
Carpi, Italy) has been approved for human and veterinary clinical practice. 
To test the efficacy of active immunotherapy through DNA electrovaccination against ROS1-
positive NSCLC, we exploited transgenic mice that harbor a latent oncogenic K-Ras allele, at the 
endogenous locus, that is capable of spontaneous activation in vivo, due to an activating mutation at 
codon 12 (K-RasG12D mice). These mice spontaneously develop NSCLC with 100% of penetrance [70]. 
In this work, we demonstrated that these mice are a reliable translational model for the study of 
human NSCLC and for investigating the effects of ROS1 targeting, as ROS1 is expressed at all stages 
of NSCLC progression. Moreover, we have generated a ROS1-positive cancer cell line, starting from 
a NSCLC that arose in a K-RasG12D mouse, that can be serially transplanted into syngeneic mice, 
offering an additional tool for studying the potential of ROS1 targeting. 
Since ROS1 is a self-tolerated antigen in mice and it is impossible to know in advance whether 
the self-homologous sequence of a given antigen is able to break immune tolerance, we evaluated the 
anti-tumor efficacy of two different plasmids that code for the optimized sequence of the self-murine 
ROS1 and for the xenogeneic human ROS1 sequence. Both DNA vaccines proved to be able to 
successfully immunize mice against ROS1 and impair ROS1-positive NSCLC growth and 
metastasization. 
2. Materials and Methods  
2.1. Mice 
Wild-type (wt) SV129 mice were provided by Charles River Labs (Wilmington, Massachusetts, 
USA). Heterozygous K-RasG12D mice, on SV129 background, were kindly provided by Dr. G. Lozano 
(University of Texas, Houston, USA). Mice were maintained in the animal house at the Molecular 
Biotechnology Center (University of Torino, Torino, Italy) under a 12-hour light–dark cycle and 
provided with food and water ad libitum. Heterozygous K-RasG12D male mice were mated with wt 
female mice. Female and male pups were genotyped as previously described [70]. Briefly, PCR 
analysis was performed on tail DNA obtained at weaning using the following primers (from 
Invitrogen, Carlsbad, California, USA): a 5’ forward wt (5’ - TGC ACA GCT TAG TGA GAC CC - 3’) 
and a 3’ reverse wt (5’ - GAC TGC TCT CTT TCA CCT CC - 3’) specific for the amplification of the K-
Ras wt allele (amplification band 220 bp) with the addition of a competitive 3’ reverse mutated primer 
(5’ - GGA GCA AAG CTG CTA TTG GC - 3’) specific for the G12D substitution, giving rise to a 390 
bp amplified band in the presence of the mutation. The resulting PCR products were run on a 1.5% 
agarose gel to discriminate the presence of the mutated K-RasG12D allele in heterozygosis. 
Individually tagged mice of the same age were treated in conformity with national and 
international regulations and policies, and all animal experiments were approved by the Faculty 
Ethical Committee and by the Italian Ministry of Health (approval number 1146/2015-PR). 
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2.2. Magnetic Resonance Imaging (MRI) 
Mice were anesthetized at different weeks of age (10, 20, and 30) via the intramuscular injection 
of a 40 μl mixture of Zoletil 100 (Virbac, Milano, Italia; 80 mg/Kg) and Rompun (Bayer, Milano, Italy; 
16 mg/Kg) diluted in phosphate buffered saline (PBS). Representative MR images of tumor 
progression in transgenic K-RasG12D mice were acquired on a Bruker Avance 300 (Bruker, Ettlingen, 
Germany) operating at 7T with ParaVision 5.1 using a 30 mm insert birdcage. T2w axial, coronal, and 
sagittal MR images, with an in-plane resolution of 117 μm, were acquired with a breath-triggered 
sequence respiratory gating to reduce lung movement artifacts, and using Rapid Acquisition with 
Refocused Echoes (RARE) sequence (typical settings TR/TE/NEX/RARE factor = 4.0 s/34.8 ms/3/16). 
A 256 × 256 acquisition matrix was used with a field of view of 30 × 30 mm2. The slice thickness was 
1 mm, and the number of slices was 18 to 20, which was sufficient to cover the entire lung so that the 
tumor volume could be measured. The T2w sequence displays the tumor location, size, and shape in 
both the left and right lungs, providing clear boundaries with normal lung tissue. To quantify the 
tumor volume over time in wt and in ROS1-vaccinated mice, images were acquired on a 1T Aspect 
M2-High Performance MRI System (Aspect Magnet Technologies Ltd., Netanya, Israel) consisting of 
an NdFeB magnet, equipped with a 35 mm solenoid Tx/Tr coil. The MR images were acquired with 
a Fast Spin Echo (FSE) sequence (TR 2800 ms; TE 44 ms; number of slices 18-20; slice thickness 1 mm; 
FOV 100 × 100 mm; matrix 256 × 256). 
2.3. Spontaneous Lung Tumor Volume Measurements 
The data analysis of MR images was performed using an open-source application, ITK-Snap 
(http://www.itksnap.org), which allows the segmentation of the lung nodules to be performed in 
three dimensions, and the calculation of the size of tumor lesions to be carried out [71]. Tumor volume 
per animal was quantified by calculating the area of visible lung hyperintense regions present in each 
axial or coronal image sequence slice (usually 18–20 per mouse) and then multiplying the sum of the 
areas by the slice thickness. The post-processing of the segmented data provided the volume (mm3) 
and displayed the shape of the segmented structure. Tumor volumes were also normalized relative 
to total lung volumes at the indicated times and expressed as the percentage of lung volume occupied 
by tumors. 
2.4. Histopathological and Immunohistochemical Analysis 
Tumors and tissues collected from wt and K-RasG12D mice were fixed in 4% formalin and 
embedded in paraffin. Sections were stained with hematoxylin and eosin (H&E) for histological 
evaluation. Immunohistochemical (IHC) staining for ROS1 was performed on 3-μm thick serial 
paraffin sections using an automated immunostainer (Ventana BenchMark AutoStainer, Ventana 
Medical Systems, Tucson, Arizona, USA) and using a primary anti-ROS1 rabbit mAb (D4D6) (Cell 
Signaling Technology, Danvers, Massachusetts, USA) diluted 1:100. ROS1 scoring was performed in 
a semiquantitative scale (from 0 to 3) based on the percentage of positive neoplastic cells showing 
cytoplasmic and/or membrane staining, as follows: 0, no staining; 1+, <10% of positive cells; 2+, 10 to 
50% positive cells; 3+, >50% positive cells. IHC staining for PD-L1 was performed in an automated 
immunostainer (Autostainer Link 48, Agilent Technology, Santa Clara, California, USA) using the CE 
IVD diagnostic kit “PDL-1 IHC 22C3 pharmDx”. Results are expressed as the exact percentage of 
neoplastic cells showing PD-L1 membrane positive staining, irrespective of the staining intensity. 
2.5. RNA Extraction and qPCR 
Normal lung tissues and primary lung adenocarcinomas were collected from wt and K-RasG12D 
mice at different stages of cancer progression (corresponding to 10, 20, and 30 weeks of age). Mice 
were sacrificed via cervical dislocation at the indicated times. Specimens for RNA extraction were 
stored in RNA later (Sigma-Aldrich, St. Louis, Missouri, USA) at 4 °C for 24 hours and then snap-
frozen in liquid nitrogen and stored at –80 ° C until use. Total RNA was isolated using an IKA-Ultra-
Turrax® T8 homogenizer (IKA-Werke, Staufen im Breisgau, Germany) and TRIzol® reagent 
Vaccines 2020, 8, 166 5 of 23 
 
(Invitrogen), according to the manufacturer’s instructions. Genomic DNA contamination was 
removed from total RNA using a DNA-free kit (Ambion, Warrington, UK) as per the manufacturer’s 
instructions. Total RNA concentration and purity were assessed using a NanoDROP 2000 
Spectrophotometer (ThermoFisher, Waltham, Massachusetts, USA). RNA quality was evaluated on 
an Agilent 2100 Bioanalyzer, according to the manufacture’s recommendations (Agilent 
Technologies). Total RNA was stored at –80 °C until use. DNase-treated RNA (1 μg) was 
retrotranscribed with RETROscript reagents (Ambion), and qPCRs were carried out using gene-
specific primers (QuantiTect Primer Assay), SYBR green, and a 7900HT RT-PCR system (Applied 
Biosystems, Foster city, California, USA). Quantitative normalization was performed on the 
expression of the housekeeping glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 18s 
ribosomal RNA genes. Relative gene expression levels were calculated using the comparative ΔCt 
method [72]. 
2.6. Cell Line. 
KL-ROS1 is a cell line that we established in vitro from a lung carcinoma that arose 
spontaneously in a 40-week-old K-RasG12D female mouse. Cells are cultured in Dulbecco Modified 
Eagle’s Medium (DMEM) supplemented with 20% heat-inactivated fetal bovine serum (FBS, Sigma-
Aldrich) and routinely checked for Mycoplasma contamination using the Mycoalert Detection Kit 
(Lonza, Zurich, Switzerland) and consistently found to be negative. In order to test ROS1 expression, 
KL-ROS1 cells were washed in PBS supplemented with 0.2% bovine serum albumin (BSA) and 0.01% 
sodium azide (Sigma-Aldrich) and stained for ROS1 after fixation and permeabilization with the 
Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences, Allschwil, Switzerland). In order 
to detect the ROS1 positivity, a primary rabbit anti-ROS1 (D4D6) mAb (Cell Signaling Technology) 
and a secondary fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit immunoglobulins 
(Dako, Santa Clara, California, USA) were used. For transplantable tumor experiments, wt mice were 
challenged subcutaneously with different doses of KL-ROS1 cells, ranging from 105 to 106. The tumor 
dimensions of the challenged mice were inspected weekly by palpation. Progressively growing 
masses >1 mm in diameter were regarded as tumors. Mice were sacrificed when the tumor exceeded 
10 mm in diameter. 
2.7. Flow Cytometry Analysis. 
In order to characterize the phenotype of splenocytes (SPC) and tumor-infiltrating immune cells, 
single-cell suspensions were derived from the spleens and from lungs of wt tumor-bearing and K-
rasG12D-vaccinated mice, as described in [73]. Cells were treated with Fc receptor blocker (BD 
Biosciences) and then stained for 30 min at 4 °C with the following antibodies: anti-CD45-VioGreen, 
anti-CD3-FITC, anti-CD4-APC/Vio770, anti-CD8-VioBlue, anti-CD49b-PE, anti-TCRγδ-PE/Vio770, 
anti-PD1-APC, anti-CD11b-FITC, anti-F4/80-PE/Vio770, anti-Ly6C-APC/Vio770, anti-Ly6G-VioBlue, 
anti-MHCII-APC (Miltenyi Biotec Bergisch Gladbach, Germany), anti-CD206-PE, and anti-CD69-
PE/Vio770 (Biolegend, San Diego, California, USA). Labeled samples were acquired on a BD 
FACSVerse and analyzed using FlowJO10.5.3 software.  
2.8. Mice Immunization through DNA Plasmid Electroporation 
The plasmids coding the extracellular and transmembrane domain of the mouse (m) and the 
human (h) ROS1 cDNA sequences were obtained from GenScript (Piscataway, New Jork, USA). 
Regarding the mROS1 plasmid, the cDNA sequence inserted was optimized in order to enhance its 
immunogenicity in mice. The ROS1 protein sequence coded by the hROS1 plasmid shows a 
homology of 80% with the mROS1 protein. Both sequences were cloned in pVAX1 plasmid 
(Invitrogen), sequenced (BMR Genomics, Padova, Italy), and amplified with EndoFree Plasmid Giga 
Kits (Qiagen Inc., Hilden, Germany). Before each immunization, mice were anaesthetized, as 
described above, and then their quadriceps muscle was injected with 50 μg of either pVAX, or mROS1 
or hROS1 plasmids diluted in 20 µl of saline solution. Immediately after the injection, two 25-ms 
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transcutaneous low-voltage electric pulses (amplitude 150 V; interval 300 ms) were administered at 
the injection site via a multiple-needle electrode connected to a CliniporatorTM (IGEA) [74–76]. For 
transplantable tumor growth experiments, wt mice were immunized twice at 14-day intervals, while, 
as far as the transgenic mouse model is concerned, 6-week-old K-RasG12D mice were randomly 
assigned to pVAX, mROS1, and hROS1 experimental groups and immunized three times at 14-day 
intervals.  
2.9. Assessment of Anti-ROS1 Cellular Response by ELISPOT 
ELISPOT analysis was performed to detect interferon (IFN)-γ release from the lymphocytes that 
were collected from vaccinated mice. Specifically, 5 × 105 SPC, collected two weeks after the second 
electrovaccination of wt mice, were plated in duplicate into nitrocellulose 96-well HTS IP plates 
(Millipore, Bedford, MA) that had been pre-coated with 5 μg/mL of purified anti-mouse IFNγ 
antibody (clone R4–6A2, BD Biosciences). SPC were stimulated for 48 hours at 37 °C with 15 μg/mL 
of the predicted H2-Db immunodominant peptide (Pep2, FACENNDFL) (Twin Helix, Rho, MI) 
derived from both the m and hROS1 protein sequences. The selection of the peptide sequence was 
based on the online peptide prediction tool SYFPEITHI provided by the University of Tubingen 
(Tubingen, Germany). Briefly, both the murine and the human ROS1 sequences were analyzed 
according to the SYFPEITHI epitope prediction algorithm described in [77], in order to identify the 
predicted H2-Db-restricted nonamers. All possible nonamers were listed on the basis of their 
probability of being processed and presented to T cells, and among them, we selected the highest-
scoring peptide shared by both sequences. 
SPC stimulated with 2 μg/mL of Concanavalin A (ConA) were used as internal technical 
controls. Plates were developed according to the manufacturer's instructions (BDTMELISPOT Set, 
BD Biosciences). 
2.10. Statistical Analysis 
Statistical differences were evaluated using GraphPad software 6.0 (GraphPad Inc., San Diego, 
California, USA). Differences in tumor incidence and mouse survival were analyzed using the 
Wilcoxon test, while differences in the tumor volumes, in the percentage of volume occupied by the 
tumor, in qPCR analysis, in anti-ROS1 antibody titers, in the number of IFN-γ-releasing SPC, and in 
the percentages of the different immune cells were analyzed using either the Student’s t-test or one-
way ANOVA.  
3. Results 
3.1. K-RasG12D Transgenic Mice are a Valuable Pre-Clinical Model for Human NSCLC. 
In order to monitor the presence and progression of spontaneous NSCLC that developed in K-
RasG12D transgenic mice with a non-invasive technique, MRI for small rodents was exploited. K-
RasG12D mice were imaged at 6, 10, 20, and 30 weeks of age (Figure 1a). Lung microlesions, which 
were observed as white opaque hyperintense regions, were already visible in 6-week-old K-RasG12D 
mice and increased in number and size in 10, 20, and 30-week-old K-RasG12D mice. Indeed, the 
segmentation analysis of the lung nodules in three dimensions clearly indicated a significant increase 
in the percentage of tumor volume occupying the lungs of 30-week-old K-RasG12D mice, compared to 
that of 6, 10, and 20-week-old K-RasG12D mice (Figure 1b). Histological analyses of the lung sections 
collected from K-RasG12D mice confirmed that the white opacities revealed by the MRI analyses 
corresponded to the small foci of lung carcinoma (Figure 1c). Neoplastic foci consisted of growths of 
polygonal atypical epithelioid cells arranged in a solid architecture, with occasional gland formation, 
and a desmoplastic reaction that proves stromal infiltration. Mucin production was very scant or 
absent. No lepidic growth nor non-invasive neoplastic proliferations were seen. The histological 
appearance of tumor foci was very similar in the different animals, irrespective of the age of the mice 
(Figure 1c).  
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It is worth noting that between the 45th and the 50th week of age, 25% of K-RasG12D mice develop 
extrathoracic metastases (Figure 1d) in the liver, skeletal muscle, and stomach, which are the same 
sites of cancer-cell dissemination found in patients affected by NSCLC [78,79]. 
Flow cytometry analysis of the lungs from 10- and 30-week-old K-RasG12D mice were performed 
to investigate the evolution of the tumor microenvironment during cancer progression, and the 
results were compared to those obtained from the lungs of age-matched wt mice. At 10 weeks of age, 
a significant increase in CD3+, CD8+ T cells, and in type-1 polarized macrophages was observed in the 
lungs of K-RasG12D mice, as compared to wt mice (Figure 1e, upper panels), suggesting that a 
spontaneous antitumor immune response was present in the early stages of NSCLC development. 
On the other hand, the T cell-mediated anti-tumoral response was decreased later in carcinogenesis 
progression (30 weeks of age) and was accompanied by a significant increase in type-2 polarized 
macrophages (Figure 1e, lower panels). This immune phenotype of the K-RasG12D lungs mirrors the 
setting of human advanced NSCLC, for which the spontaneous conversion from an anti-tumorigenic 
to a pro-tumorigenic microenvironment has been described to occur over time [80–82]. Moreover, 
PD-L1 was detectable by means of IHC in all samples tested (data not shown), with a percentage of 
positive tumor cells ranging from 15% to 40%, similar to what was observed in most human NSCLC 
[83]. 
These data further support the high translational value of the K-RasG12D mouse model. 
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Figure 1. Characterization of lung cancer progression in K-RasG12D mice. (a) Representative MRI 
images acquired with a 7T high field scanner of K-RasG12D mice at 6, 10, 20, and 30 weeks of age (N = 
3 mice for each time point). White hyperintense regions, indicated by arrows, are tumors. (b) 
Percentage (mean + standard deviation (SD)) of tumor volume occupying the lungs of K-RasG12D mice 
(N = 5–16) at indicated weeks of age. Statistically significant differences were calculated using the 
Student’s t-test: *, 0.05; **, 0.008. (c) Representative hematoxylin and eosin (H&E) evaluation of lung 
sections from K-RasG12D mice at the initial (10 weeks of age, left panel) and late (30 weeks of age, 
middle, and right panels) stages of tumor progression. Black arrows indicate some figures of 
microglandular formation; red arrows indicate collagen deposition in desmoplastic stromal reaction. 
N = 4 mice were analyzed at indicated time points. (d) Representative H&E images of extrathoracic 
metastatic lesions in the liver, skeletal muscle, and stomach, collected from a 48-week-old K-RasG12D 
mouse. N = 4 mice were analyzed. (e) Cytofluorimetric analysis of immune infiltrates of the lungs (N 
= 3–12) from 10 (upper panels) and 30-week-old (lower panels) wt (black bars) and K-RasG12D (grey 
bars) mice. Graphs show the percentage ± SD of CD45+ cells expressing CD3 (left panels), CD8, and 
CD4 (middle panels) and of the M1 state (CD11b+ f4/80+ MHCII+ CD206-), M2 state (CD11b+ f4/80+ 
MHCII- CD206+), and M1/M2 transitional state (CD11b+ f4/80+ MHCII+ CD206+) macrophages (right 
panels). Statistically significant differences were calculated using the Student’s t-test: *, 0.01; **, <0.005. 
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3.2. Autochthonous NSCLC and Extrathoracic Metastases of K-RasG12D Mice Express the ROS1 
Oncoantigen. 
To validate the use of K-RasG12D mice as a model with which to study the effects of ROS1 
targeting in NSCLC, we evaluated ROS1 expression in the lungs and extrathoracic lesions of these 
mice. qPCR analyses of the lungs collected from 10, 20, and 30-week-old K-RasG12D mice and the 
corresponding aged-matched wt controls revealed the significant overexpression of ROS1 mRNA in 
transgenic mice, as compared to controls, at each time point analyzed (Figure 2a and Figure S1). The 
expression of ROS1 during lung tumorigenesis was also confirmed at the protein level by means of 
IHC staining (Figure 2b). Indeed, while no staining was observed in the normal lung parenchyma of 
wt or K-RasG12D mice, ROS1 protein expression was found in 100% of neoplastic lung lesions from K-
RasG12D mice, although at variable extents and intensities (Figure 2b). It is worth noting that different 
protein-expression patterns were observed in separate nodules collected from the same lung sample 
(Figure 2b, middle and right panels), suggesting great intratumor heterogeneity in the lesions.  
However, no correlation between ROS1 expression and tumor progression was observed, being 
both mRNA and protein levels constantly high throughout all the analyzed stages. These data fit well 
with our previous transcriptional microarray analysis of the lungs of double transgenic K-
RasG12D/p53R172HΔg mice [84] from which ROS1 mRNA resulted significantly increased in K-
RasG12D/p53R172HΔg double transgenic mice, as compared to wt mice, at the different time points 
analyzed (Figure S2), despite no correlation between ROS1 expression levels and tumor progression 
being observed. 
Interestingly, when analyzed after IHC staining, metastatic lesions of K-RasG12D mice showed a 
heterogeneous pattern of ROS1 protein expression, from 0 in the stomach to 3 in the liver and skeletal 
muscle (Figure 2c), highlighting the potential role that ROS1 plays as a target for the therapy of both 
primary tumors and derived metastases. 
 
Figure 2. Receptor tyrosine kinase ROS1 expression in lung tumors and metastases from K-RasG12D 
transgenic mice. (a) qPCR for ROS1 mRNA expression levels in lungs from 10, 20, and 30-week-old 
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wt and K-RasG12D mice (N = 3–4). The results are expressed as Delta CT (-Dct) between the CT value of 
the ROS1 gene and the CT value of the GAPDH housekeeping gene. Each dot represents the evaluation 
of the relative mRNA expression level in a single mouse. Statistically significant differences were 
calculated using the Student’s t-test: *, 0.02; ***, <0.0006; ****, <0.0001. (b) Representative images of 
ROS1 IHC staining of lung samples from a wt (normal lung) mouse, a 10-week-old K-RasG12D mouse, 
and two different lung lesions from the same 30-week-old K-RasG12D mouse. The ROS1 IHC score was 
attributed as described in the Materials and Methods section. N = 4 mice were analyzed. (c) 
Representative images of the ROS1 IHC staining of metastatic lesions found in a 48-week old K-
RasG12D mouse (liver, skeletal muscle, and stomach). N = 4 mice were analyzed. 
3.3. Anti-ROS1 Electrovaccination Impairs the Growth and Metastasization of ROS1-Positive 
Transplantable K-RasG12D NSCLC. 
A murine NSCLC cell line was generated and established starting from a K-RasG12D lung tumor. 
Flow cytometry analysis demonstrated that these cells are ROS1-positive (Figure 3a), and therefore, 
we called this newly generated cell line KL-ROS1. When injected subcutaneously, KL-ROS1 cells gave 
rise, in all wt mice, to palpable tumors that reached 10 mm mean diameter in about 30 days (Figure 
3b). In accordance with the observations of spontaneous lung tumor samples, IHC staining confirmed 
that KL-ROS1 tumors do express high levels of the ROS1 protein (Figure 3c), although with 
heterogeneous intensity (from score 1+ to 3+) in different mice. Similar to the K-RasG12D mouse model, 
PD-L1 was co-expressed with ROS1 in KL-ROS1 tumors (data not shown). Moreover, subcutaneous 
KL-ROS1 tumors spontaneously metastasize to the lungs, and the lung lesions preserve ROS1 
overexpression (Figure 3d). 
 
Figure 3. Characterization of KL-ROS1 cell line. (a) Representative cytofluorimetric analysis of anti-
ROS1 (D4D6) (red line) or control unrelated IgG isotype Ab (green line) staining on KL-ROS1 cells. 
(b) Graph showing the tumor growth of KL-ROS1 cells injected subcutaneously in wt mice at different 
doses. Data are expressed as mean tumor diameters ± SD for each experimental group (N = 3–5 mice). 
(c,d) Representative H&E (left panels) and IHC staining for the ROS1 protein (right panels) of (c) an 
explanted 10 mm mean diameter KL-ROS1-derived tumor and (d) a spontaneous KL-ROS1-derived 
lung metastases. N = 4 mice were analyzed. 
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To test the potential of ROS1 immune-targeting to inhibit KL-ROS1 tumor growth, we 
electrovaccinated wt mice twice, at a 14-day interval, with plasmids coding for the extracellular and 
transmembrane sequence of either the m or hROS1 protein. Two weeks after the second 
immunization, the animals were challenged subcutaneously with 2 x 105 KL-ROS1 cells (Figure 4a). 
A significant increase in overall survival was observed in mice vaccinated with mROS1 and hROS1 
plasmids, as compared to pVAX controls (Figure 4b). Interestingly, two out of eight mice (25%) 
vaccinated with mROS1 (Figure 4c, middle panel), and one out of nine mice (11%) vaccinated with 
hROS1 (Figure 4c, right panel) rejected the tumor. When these tumor-free mice were re-challenged 
in the opposite flank with the same dose of KL-ROS1 cells, they were protected (not shown), 
suggesting that anti-ROS1 DNA electrovaccination efficiently induces an immune memory against 
ROS1 protein-expressing cells. 
mROS1 and hROS1 vaccination also impacted upon the ability of KL-ROS1 cells to give rise to 
metastases. Indeed, while 100% of analyzed lungs collected from mice immunized with the pVAX 
empty vector displayed metastatic lesions, only 25% of mROS1- and 75% of hROS1-electrovaccinated 
mice showed lung metastases (Figure 4d). Nevertheless, the expression pattern of ROS1 protein was 
similar in mROS1- and hROS1-vaccinated mice, as compared to control mice vaccinated with the 
empty pVAX vector, both in subcutaneous and lung lesions (Figure 5). Furthermore, the pattern and 
the intensity of the PD-L1 expression detectable by IHC did not change in ROS1 electrovaccinated 
and control mice in all tested samples (data not shown).  
Collectively, these data suggest that ROS1 DNA electrovaccination may possess efficacy in 
hampering tumor growth and metastatic spread. 
 
Figure 4. Effect of anti-ROS1 DNA vaccination on transplantable KL-ROS1 tumors. (a) Protocol 
timeline for DNA vaccination through electroporation. (b) Overall survival curves of wt mice 
electrovaccinated with pVAX (black line; N = 7 mice), mROS1 (red line; N = 8 mice), and hROS1 (blue 
line; N = 9 mice) plasmids. Survival was calculated considering the time (in days) in which KL-ROS1 
tumors reached 10 mm in mean diameter. Statistically significant differences in the survival times of 
m and hROS1-electrovacinated mice, as compared to control mice that were electrovaccinated with 
pVAX, were analyzed using the Wilcoxon test: *, 0.03, *, 0.05. (c) Tumor growth of KL-ROS1 cells 
injected into pVAX- (black line, left panel, N = 7 mice), mROS1- (red line, middle panel, N = 8 mice), 
and hROS1- (blue line, right panel, N = 9 mice) electrovaccinated wt mice. Each line represents the 
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growth of a single tumor. (d) Percentage of non-metastatic (gray bar) or metastatic (black bar) lungs 
collected from control, mROS1-, and hROS1-electrovaccinated tumor-bearing mice (N = 4 mice). 
 
Figure 5. ROS1 expression in transplantable tumors and metastases from wt, and mROS1- and 
hROS1-vaccinated mice. Representative images of the H&E staining (left panels) and IHC analysis of 
ROS1 protein expression (right panels) on explanted subcutaneous tumors (a) and lung metastases 
(b) from pVAX- (upper panels), mROS- (middle panels), and hROS- (lower panels) electrovaccinated 
mice. The ROS1 IHC score is indicated in each panel. N = 4 mice were analyzed. 
3.4. Immune Response Induced by Anti-ROS1 Electrovaccination. 
In order to study the mechanisms that may potentially be associated with the impairment of KL-
ROS1 tumor growth that was observed in wt mice vaccinated against ROS1, we investigated the 
immune response induced by the electrovaccination.  
Firstly, the presence of anti-mROS1 and anti-hROS1 antibodies was checked in the sera from 
immunized mice, two weeks after the second electrovaccination. As recombinant m and hROS1 
proteins are not commercially available, protein fragments (purity <85%) from the mROS1 (aa 29 to 
1038) and hROS1 (aa 28 to 1042 and 1043 to 1859) extracellular domains were used as targets in ELISA. 
No significant differences were found in the sera from ROS1 and pVAX electrovaccinated mice 
(Figure S3a). However, when sera from each experimental group were pooled and tested against 
NIH-3T3 murine fibroblasts transfected with ROS1-coding plasmids, faint binding was evident in the 
immunofluorescence. In particular, while sera from pVAX electrovaccinated mice did not stain NIH-
3T3 cells that were transfected with either mROS1 or with hROS1, those from mice that were 
electrovaccinated with mROS1 and hROS1 were able to stain the NIH-3T3 cells transfected with 
mROS1 and hROS1, respectively (Figure S3b). These data indicate that a specific anti-ROS1 antibody 
response may be induced following ROS1 electrovaccination.  
Then, we evaluated the effects of ROS1 electrovaccination on the frequency of various immune 
cell populations in the SPC of treated mice, using flow cytometry. While no differences were found 
in the percentage of CD4+ T, CD8+ T, and natural killer (NK) cells (data not shown), the percentage of 
NK cells that expressed the activation marker CD69 in SPC from both m and hROS1 electrovaccinated 
mice was significantly increased compared to controls (9.3 ± 3.8; 9.0 ± 2.8; 5.2 ± 1.2; Student’s t-test: *, 
0.02; **, < 0.006). Moreover, the frequency of γδ T cells in SPC from both m and hROS1 was twice that 
found in pVAX electrovaccinated mice (Figure 6a), (3.3 ± 0.7; 4.3 ± 1.5; 1.1 ± 0.6; Student’s t-test: *, 
0.02; **, < 0.006). 
In order to evaluate the ability of ROS1 electrovaccination to induce a ROS1-specific CD8+ T cell 
response, SPC from electrovaccinated mice were tested in an IFN-γ ELISPOT assay after in vitro 
restimulation with a synthetic nonamer peptide (FACENNDFL) that is shared by m and hROS1 
proteins and predicted to be properly presented on H-2Db molecules. Specific IFN-γ-releasing T cells 
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were only found in the SPC from one mROS1 and a few hROS1 electrovaccinated mice (Figure 6b), 
although no significant differences were observed among groups. 
Taken together, these results suggest that ROS1 electrovaccination is potentially immunogenic 
in mice as demonstrated by the increase of activated NK cells and in the frequency of γδ T cells and 
by the induction of IFN-γ releasing CD8+ T cells in some vaccinated mice. These cells might contribute, 
together with antibodies and other immune mechanisms that we have not yet explored, to the 
significant increase in overall survival and to tumor rejection that was observed in immunized mice. 
 
Figure 6. Anti-ROS1 cellular immune response induced by electrovaccination in wt mice. (a) 
Cytofluorimetric analysis of SPC collected from pVAX- (black), mROS1- (red), and hROS1- (blue) 
electrovaccinated wt mice (N = 6–12). CD45+ leukocytes were gated, and CD3+ CD4+ CD69+ cells were 
identified as activated CD4+ T cells, CD3+ CD8+ CD69+ were identified as activated CD8+ T cells, CD3- 
CD49b+ CD69+ were identified as activated NK cells, and CD3+ γδ+ were identified as γδ T cells. 
Results are expressed as a percentage of positive cells using violin plots, which represent the mean 
and the 95% CI of each group of data. Statistically significant differences in the percentages of γδ T 
cells and activated CD4+ and CD8+ T cells, and NK cells in ROS1-electrovacinated and control mice 
were analyzed using the Student’s t-test: *, 0.02; **, <0.006. (b) The detection of the number of IFN-γ-
producing cells when SPC that were collected from pVAX- (black; N = 4 mice), mROS1- (red; N = 10 
mice), and hROS1- (blue; N = 10 mice) electrovaccinated wt mice were stimulated with the H2-Db 
immunodominant ROS1-derived peptide (Pep2, FACENNDFL). Results are expressed as spot-
forming cells (SFC) per million of SPC plated ± SD and were analyzed using the Student’s t-test. 
3.5. Anti-ROS1 DNA Vaccination Impairs the Development of Spontaneous Lung Cancers in K-RasG12D 
Transgenic Mice. 
In order to evaluate whether anti-ROS1 DNA electrovaccination can also impair aggressive K-
RasG12D-driven autochthonous ROS1-positive lung carcinogenesis, 6-week-old K-RasG12D mice were 
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electrovaccinated three times, at two-week intervals, with either the mROS1 plasmid, hROS1 
plasmid, or the control empty vector pVAX (Figure 7a). Since the percentage of the lung volume 
occupied by tumors is very similar among K-RasG12D mice imaged at 6 weeks of age (from 0.375% to 
1.389%; Figure 1a,b), animals were randomly distributed in the different immunization groups. The 
presence of lung adenocarcinomas was monitored and quantified at 10, 20, and 30 weeks of age by 
MRI.  
All vaccinated mice developed lung tumors as expected in this very aggressive model. However, 
at 30 weeks of age, a clear reduction in the lung volume occupied by the tumors was observed in 
ROS1-electrovaccinated mice, compared to the age-matched controls (Figure 7b). Lung lesions were 
fewer and smaller in most of the ROS1 electrovaccinated mice than in the age-matched controls 
(Figure 7c). In those K-RasG12D electrovaccinated mice in which it was possible to monitor the lung 
tumor progression by MRI over time, lower growth speed was observed in all m and hROS1 
electrovaccinated compared to control mice (Figure 7d). Notably, a decrease in the total tumor 
volume was observed between the 20th and the 30th week of age in 2 out of 4 mROS1 and in 1 out of 
3 hROS1 electrovaccinated mice (Figure 7d). 
Overall, these results suggest that ROS1 electrovaccination may play a role in controlling the 
growth of the very aggressive autochthonous NSCLC of K-rasG12D mice. 
 
Figure 7. Impact of anti-ROS1 DNA vaccination on the autochthonous lung carcinogenesis of K-
RasG12D mice. (a) Protocol timeline for DNA electrovaccination. (b) Percentage (mean + SD) of tumor 
volume occupying the lungs in 10, 20, and 30-week-old pVAX (black bars), mROS1 (red bars), and 
hROS1 (blue bars) electrovaccinated K-RasG12D mice (N = 4–12). (c) Representative MRI images of 30-
week-old K-RasG12D mice immunized with pVAX (left panel), mROS1 (middle panel), and hROS1 
(right panel) acquired with a 7T high field scanner (N = 3 mice for each time point). White 
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hyperintense regions indicated by arrows are tumors. (d) Tumor progression of pVAX- (black bars; 
N = 4 mice), mROS1- (red bars; N = 4 mice), and hROS1- (blue bars; N = 3 mice) electrovaccinated K-
RasG12D mice over time. Each single mouse was imaged by MRI at 10, 20, and 30 weeks of age. Data 
are shown as percentage of tumor volume occupying the lungs of each single mouse. 
In order to monitor the vaccine-induced immune response, sera from K-RasG12D mice were tested 
in ELISA using mROS1 (aa 29 to 1038) and hROS1 (aa 28 to 1042 and 1043 to 1859) protein fragments. 
Similarly to observations in wt mice, no differences in anti-ROS1 antibody levels were detected 
(Figure S4a). When the tumor infiltrating cells from 30-week-old K-rasG12D mice were studied by flow 
cytometry, a slight increase in the percentage of CD4+ T and NK cells that expressed the CD69 
activation marker, and a slight increase in the γδ T cells was found in m and hROS1 electrovaccinated 
mice, compared to controls (Figure S4b). As far as PD-L1 expression is concerned, no differences in 
the percentage of PD-L1-positive cells were observed in the lung lesions of ROS1 electrovaccinated 
and control K-rasG12D mice (data not shown).  
4. Discussion 
Lung cancer is the leading cause of cancer mortality [85], with NSCLC accounting for 
approximately 85% of cases. As the earlier stages are relatively asymptomatic, many patients present 
advanced disease and metastases at diagnosis. The unfeasibility of tumor resection in the majority of 
cases and the metastatic spread of the disease lead to severe complications, which usually precede 
the fatal stages by a few months, and conventional therapies (i.e., chemotherapy and radiotherapy) 
are relatively ineffective. For this reason, NSCLC still remains a hot, unmet topic in the oncology 
panorama, prompting research toward the development of novel and more effective therapies.  
Several genomic NSCLC subsets have been identified, progressively modernizing treatment 
strategies toward “personalized medicine”. Moreover, novel molecular aberrations, beside those of 
EGFR and ALK proteins, have been investigated and characterized, with chromosomal 
rearrangements and the overexpression of ROS1 gaining a great deal of interest [86–88]. 
Constitutively active ROS1 tyrosine kinase has been proven to be a potent tumorigenic driver that 
activates downstream oncogenic signals, leading to increased cell proliferation and survival. In fact, 
crizotinib has been FDA-approved for the treatment of ROS1-positive NSCLC, increasing patient 
survival [40]. However, as for other tyrosine kinase inhibitors, the majority of patients progressively 
develop resistance to crizotinib [89–91]. Herein, we propose using active immunotherapy to induce 
the patient’s own immune system to develop a long-lasting anti-tumor immune response against 
ROS1, as an alternative treatment. To this end, in this work, we have exploited two murine models 
of ROS1-positive NSCLC, the KL-ROS1 cell line and the transgenic K-RasG12D mice, to test the efficacy 
of DNA electrovaccination against ROS1. The KL-ROS1 cell line was derived from a lung lesion in a 
K-RasG12D mouse. When injected subcutaneously into syngeneic mice, KL-ROS1 cells gave rise to fast-
growing ROS1-positive tumors in the site of injection and to lung metastases. Transgenic K-RasG12D 
mice spontaneously develop NSCLC early in their life, and about 25% of them display extrathoracic 
metastases when they succumb for the disease at 11–12 months of age. We detected ROS1 
overexpression at both mRNA and protein levels in the primary lung lesions during all the stages of 
cancer progression and in the extrathoracic metastases developed in several organs of K-RasG12D mice. 
By contrast, ROS1 was not detected in normal lung tissue, mirroring the human situation in which 
ROS1 is not, or is just barely, expressed in healthy lung tissue, bronchial basal cells, peri-bronchial 
glands, and smooth muscle cells [92]. Similarly, cancer cells were ROS1-positive in the metastatic 
sites. 
Plasmids coding for ROS1 (50 μg/injection) were administered intramuscularly. In order to 
increase plasmid immunogenicity, two 25-ms transcutaneous low-voltage electric pulses (amplitude 
150 V; interval 300 ms) were applied to the site of injection using the Cliniporator device, which is an 
instrument that has already been approved for human use, and that has provided striking results in 
several clinical trials of electrochemotherapy [93–98]. The DNA dose, the schedule of administration, 
and the electroporation protocol were derived from those successfully used to immunize mice against 
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ErbB2 and other antigens [53,54,74–76]. The impossibility of predicting whether the 
electrovaccination using the murine homologous sequence of ROS1 would be able to break immune 
tolerance, leading to a detectable and effective anti-tumor immune response, spurred us to test the 
efficacy of both the murine and the human ROS1-coding plasmids (80% homology between human 
and murine ROS1 sequences). Indeed, it has been clearly demonstrated that heterologous sequences 
provide the heteroclitic peptides necessary to overcome T cell tolerance [99], and when they share a 
good degree of homology (ranging from 80% to 95%) with the self sequence [100], an effective cross-
reactive immune response can be achieved [53–55]. The demonstration of the effectiveness of both 
DNA vaccines lays the basis for the design of chimeric murine/human ROS1 vaccines, which combine 
xenogeneic and homologous DNA sequences, as we previously did for other antigens [53–55].  
When electrovaccination was used to prevent the growth of the transplantable KL-ROS1 cell 
line, significantly increased survival was observed in the electrovaccinated mROS1 and hROS1 mice, 
compared to the control mice. The few ROS1 electrovaccinated mice that completely rejected the KL-
ROS1 cells developed an effective anti-tumor immune memory and were thus protected from a 
second challenge of KL-ROS1 tumor cells. Moreover, 25% of mROS1 and 75% of hROS1 
electrovaccinated mice were protected from the development of lung metastases. Low levels of 
specific antibodies were found in ROS1 electrovaccinated mice, and this could justify the absence of 
ROS1 down-regulation observed in the subcutaneous tumors and lung metastases. However, a 
significantly higher frequency of γδ T cells and activated NK cells was observed in ROS1 than in 
control electrovaccinated mice. Furthermore, IFN-γ-secreting CD8+ T cells that react against the H-
2Db immunodominant ROS1-derived peptide were clearly evident in 50% of hROS1 
electrovaccinated mice and barely detectable in just 10% of mROS1 electrovaccinated mice. Central 
tolerance mechanisms, such as the deletion of the T-cell clone that reacts against the tolerated mROS1 
protein, may be responsible for this absence of measurable CD8+ T cell reactivity. 
The weak anti-ROS1 antibody response, together with the heterogeneity in the induced cellular 
immune response, highlights the need to improve the vaccination protocol, including the plasmid 
dose, the number of vaccinations, and the physical parameters used for muscle electroporation. 
Nevertheless, these data are a proof of concept of the potential efficacy of anti-ROS1 
electrovaccination in hampering tumor growth and the metastatic spread of NSCLC. This is even 
more evident if we consider the results obtained in the spontaneous and aggressive K-RasG12D model, 
in which clear disease control was evident in both m and hROS1 electrovaccinated mice. As for wt 
mice, the involvement of γδ T and activated NK cells can also be envisaged in this setting, as shown 
by the presence of these cells in the lungs of 30-week-old ROS1 electrovaccinated K-RasG12D mice. The 
importance of these cell populations in the lung cancer has recently gained a lot of attention. There 
are several reports highlighting that properly stimulated γδ T cells can recognize and kill lung cancer 
cells, while they are altered in advanced NSCLC [101–104]. Along the same line, several studies have 
suggest that NK cells have a robust protective role against tumors in the early stages of lung cancer, 
but that they become dysfunctional in the late stages, allowing tumor evasion to occur [105,106]. 
Therefore, it is possible that the NK cell activation and γδ T cell expansion that are mediated by ROS1 
electrovaccination may prolong their functionality and contribute to lung cancer impairment. 
On the basis of these results, we can state that anti-ROS1 DNA electrovaccination has the 
potential to impair NSCLC progression, even if it is not able to completely block lung carcinogenesis. 
However, it is important to note that, as in human NSCLC, constitutively active K-Ras expression 
also induces an immunosuppressive tumor microenvironment [82], which may contribute to the 
limited effectiveness of our vaccines, in these murine K-RasG12D models. In particular, we have 
observed the recruitment of CD8+ T cells and M1-type macrophages in the lungs of K-RasG12D mice in 
the early stages (10 weeks of age) of NSCLC progression, which hints at the existence of a 
spontaneous anti-tumor immune response. However, at an advanced stage of the disease (30 weeks 
of age), a significant rise in the pro-tumorigenic M2-type macrophages percentage was found, which 
switches the microenvironment to an immunosuppressive one. Moreover, the high expression of PD-
L1 in both transplantable and spontaneous K-RasG12D-based models, which is not altered by 
vaccination, further contributes to dampening the immune response. 
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The inhibition of the PD1/PD-L1 axis using CIs has provided significant benefits for the 
treatment of NSCLC patients. However, resistance to treatment occurs frequently. Recent reports 
have demonstrated that one of the major causes of this resistance is the accumulation of M2-type 
macrophages at the tumor site [107,108]. For this reason, the concomitant targeting of M2-type 
macrophages and CI administration has been proposed as a promising strategy that may increase the 
efficacy of each therapy alone [109]. The availability of the K-RasG12D-based models of ROS1-positive 
NSCLC, described herein, will allow us to test whether adding ROS1 targeting to this combined 
treatment would result in an even more effective anti-tumor strategy—one that could ensure the 
long-lasting and specific activation of the cellular immune response. 
As the ROS1 protein is deregulated in a wide range of tumors other than NSCLC, including 
brain [110–113], breast [26], liver [114], colon [115], stomach [116], ovarian [117] and oral carcinomas 
[25], and chronic myelomonocytic leukemia [118], the development of ROS1 electrovaccination may 
also provide a new therapeutic option for patients affected by these ROS1-expressing cancers. 
5. Conclusions 
In summary, we have demonstrated that a potentially effective anti-ROS1 immune response has 
been induced using DNA electroporation in a NSCLC murine model, and this may be a valuable 
proof of concept for further evaluation of the possibility of exploiting this strategy, in combination 
with others, in the treatment of the wide range of ROS1-expressing tumors. 
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